Morphotek Inc. Announces Initiation of a Sponsored Research Agreement (SRA) with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic Cancer

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the company has entered into a sponsored research agreement (SRA) with Hokkaido University to evaluate the anti-tumor effect of amatuximab (MORAb-009) for advanced pancreatic cancer. Funding from this grant will support a pre-clinical study to evaluate the potential of amatuximab alone and in combination with gemcitabine in an adjuvant setting.

Back to news